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Abstract
Background: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily
acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to
their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the
baseline characteristics of this cohort.
Methods: HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4
count $250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa.
Demographic, behavioral, clinical and laboratory characteristics were assessed.
Results: Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had
cohabitated for a median of 5 years (range 2–9) with 28% reporting unprotected sex in the month prior to enrollment.
Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-
diagnosed sexually transmitted infections were uncommon (,5%), except for Trichomonas vaginalis in 14% of HIV-1
infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma
RNA was 4.2 log10 copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender
(+0.24 log10 copies/mL; p,0.001) and CD4 count (20.25 and 20.55 log10 copies/mL for CD4 350–499 and .500 relative to
,350, respectively, p,0.001).
Conclusions: The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa
at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in
preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1
transmission.
Trial Registration: ClinicalTrials.gov NCT00194519
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Introduction
Worldwide, herpes simplex virus type 2 (HSV-2) is the most
common cause of genital ulcer disease (GUD), with seroprevalence
ranging from 22% to 60% in HIV-1 susceptible persons and often
.70% among HIV-1 infected populations [1]. Numerous
epidemiological studies have indicated that HSV-2 and HIV-1
interact to promote acquisition and transmission of each virus.
Asymptomatic and symptomatic HSV-2 reactivation is associated
with increased HIV-1 levels in blood [2,3], cervical [4,5] and
rectal secretions [6], and semen [7]. Furthermore, observational
studies in Rakai, Uganda found self-reported GUD in the prior 10
months among HIV-1 infected persons was associated with a 4-
fold increased per contact risk of HIV-1 transmission [8].
Mathematical modeling studies suggest that the population-
attributable risk of HSV-2 for HIV-1 acquisition in areas of high
HSV-2 prevalence, such as sub-Saharan Africa, is between 25%
and 50% [9,10,11].
These findings raise the possibility that HSV-2 suppression,
using standard doses of acyclovir [12] in HSV-2/HIV-1 co-
infected individuals, could reduce HIV-1 transmission to their
HIV-1 susceptible partners. A direct test of this hypothesis requires
a clinical trial enrolling HIV-1 serodiscordant couples in which the
HIV-1 infected partner is co-infected with HSV-2 and random-
ized to daily antiviral therapy for HSV-2 suppression or matching
placebo and the outcome (HIV-1 transmission) is measured in the
HIV-1 susceptible partner. However, an efficacy trial requires
recruitment of greater than 3000 HIV-1 serodiscordant couples if
the annual HIV-1 transmission rate is 4%. Numerous challenges
exist for this type of study design including recruitment and
retention of both partners in HIV-1 serodiscordant couples,
reluctance of individuals, particularly men, and couples to be
tested for HIV-1, the need for couples to disclose their HIV-1
status to partners, and skepticism, among counselors and in
communities where couples were recruited, about the possibility of
HIV-1 serodiscordance in the context of a committed partnership.
The Partners in Prevention HSV-2/HIV-1 Transmission Study
(‘‘Partners Study’’) is a randomized, placebo controlled clinical
trial of acyclovir for HSV-2 suppression to reduce HIV-1
transmission in HIV-1 serodiscordant couples in multiple sites in
East and Southern Africa. Enrollment into the clinical trial began
in November 2004 and was completed in April 2007. Here we
describe baseline characteristics of this unique cohort of HIV-1
serodiscordant couples recruited into this trial of HSV-2
suppression for HIV-1 prevention.
Methods
Study design
HIV-1 discordant couples for the Partners Study were recruited
from seven sites in East Africa, and seven sites in Southern Africa
(Table 1). The HIV-1 infected partners were randomly assigned to
receive acyclovir (400 mg orally twice daily; Ranbaxy Inc.,
Haryana, India) or matching placebo. The primary clinical trial
endpoint is seroconversion in the initially HIV-1 susceptible
partner. We based sample size calculations for this study on an
expected overall annual HIV-1 incidence rate of 4% in the
placebo arm. Although estimates of incidence in HIV-1 discordant
couples vary widely, the 4% incidence assumption was derived
from prospectively-followed African HIV-1 serodiscordant couples
demonstrating an annual HIV-1 incidence of 6.2–8.2% [13],
combined with the assumption that regular HIV-1 prevention
counseling at scheduled visits (monthly for the HIV-1 infected
partner and quarterly for the HIV-1 uninfected partner) would
further reduce incidence.
Enrollment
Recruitment of HIV-1 serodiscordant heterosexual couples for
this trial has been described [14]. Briefly, counselors from Partners
Study clinics and affiliated community voluntary counseling and
testing (VCT) centers were trained in specialized skills in risk
assessment, pre- and post-HIV test couples counseling through a
training curriculum for a Couples HIV-1 Counseling and Testing
(CHCT) developed in a collaborative effort between Rwanda
Zambia HIV Research Group (Dr. Susan Allen), Liverpool VCT,
Kenya (Dr. Miriam Taegtmeyer), and US Centers for Disease
Control and Prevention [15]. Couples who tested as HIV-1
serodiscordant through community VCT or at a Partners study
clinic were offered information about the study and referred for
study screening.
HIV-1 serodiscordant couples were eligible for enrollment if
they were sexually active (defined as vaginal or anal intercourse at
least three times in the last three months), able to provide
independent informed consent for participation in the study,
planned to remain in the relationship for the duration of study
follow-up (maximum 24 months), and provided locator informa-
tion. Both partners consented to disclose HIV-1 test results to one
another. Couples were ineligible if either partner was co-enrolled
in another HIV-1 prevention or treatment trial, if the HIV-1
infected woman was pregnant based on self-report or urine testing
at enrollment, and if the HIV-1 infected partners were excluded if
they had a history of AIDS-defining diagnoses by WHO criteria or
were taking antiretroviral therapy (ART) at the time of enrollment.
Laboratory eligibility requirements for enrollment of the HIV-1
infected partners included local site testing showing positive HIV-1
enzyme immunoassay (EIA), positive Focus HSV-2 EIA (see
below), and CD4 cell count $250 cells/mcL. The only laboratory
eligibility requirement for HIV-1 susceptible partners was HIV-1
EIA negative results.
Although condom use was not an eligibility requirement, all
study participants were provided information and individuals and
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adherence and family planning, free condoms, and access to ART
if clinically indicated, based on clinical symptoms, CD4 testing,
and in accordance with national guidelines.
Data collection
Demographic, behavioral and clinical data were collected from
enrolled participants through interviewer-administered questions
using forms translated into local languages and back translated to
ensure appropriate content. Data forms were scanned and entered
using intelligent character recognition (ICR) DataFax software
(DataFax, ver 3.7-004, Clinical DataFax Systems Inc., Hamilton,
Ontario, Canada) and centrally double-verified by independent
data technicians.
Laboratory testing
Study clinics screened potential study participants for HIV-1
using paired commercial HIV-1 rapid tests run in parallel. HIV-1
3
rd or 4
th generation enzyme immunoassays (EIA) were used to
confirm concordant positive paired rapid-assay reactive results at
the local laboratories (Table 1). Couples in which either partner
had discrepant results from their paired HIV-1 rapid assays were
excluded from study enrollment.
HSV-2 serostatus was assessed at the local laboratories using
HerpeSelect HSV IgG ELISA (‘‘Focus’’; Focus Technologies,
Cypress, CA, USA). Samples with a Focus index value $3.5, were
considered HSV-2 seropositive. In addition, HIV-1 infected
participants with a Focus index value between 1.1 and 3.4,
potentially indicative of HSV-2 seroconversion, had serum sent to
the University of Washington; those which were positive by
Western blot (WB) were also considered HSV-2 seropositive [16].
The protocol required HIV-1 infected partners to be screened for
HSV-2 seropositivity by Focus EIA at the local study site, whereas
there was no eligibility requirement for HSV-2 serostatus of HIV-1
negative partners. For this analysis, HSV-2 serostatus of HIV-1
negative enrolled partners is based on batched HSV-2 WB
confirmation performed at the University of Washington.
CD4 testing of HIV-1 infected participants was performed at the
study site using FacsCount or FacsCalibur Instrumentation (BD
Biosciences,SanJose,USA).Plasmacollectedinacidcitratedextrose
(ACD) from HIV-infected participants was assessed for HIV-1 RNA
level through batch testing at the University of Washington using the
96-test COBAS AmpliPrep/COBAS TaqMan HIV-1 RNA assay,
version 1.0, (Roche Diagnostics, Indianapolis, IN, USA). Plasma
specimens were diluted 1:5 dilution with 106 phosphate buffered
saline (Invitrogen-GIBCO, Carlsbad, CA, USA) for the assay with a
limit of quantification of 240 RNA copies/mL.
Sites performed syndromic diagnosis for the management of
sexually transmitted infections. Syphilis serology was performed at
all sites, using rapid plasma reagin (RPR) with confirmation by
microhemagglutination test for T. pallidum (MHA-TP) at sites with
that capacity. Participants with positive syphilis serologies received
syphilis treatment per national guidelines. Cervical and urine
samples were archived for batch testing for Neisseria gonorrhoeae,
Chlamydia trachomatis and Trichomonas vaginalis at the University of
Washington. Testing for N. gonorrhoeae and C. trachomatis was
performed according to the manufacturer’s protocol (APTIMA
Combo 2 assay, Gen-Probe, San Diego, CA, USA). Testing for T.
vaginalis (TV) was performed using a research assay with TV
analyte–specific and APTIMA General Purpose Reagents [17].
Specimens yielding consistent relative light unit values .100,000
were considered positive for T. vaginalis.
Evaluation of Quality Assessment (EQA)
All assays for study eligibility were performed at site local
laboratories, specifically HIV-1 serology (rapid assays and EIA),
HSV-2 Focus ELISA, and CD4 counts; and these were subjected
to external EQA panels. An HSV-2 proficiency panel was
developed at the University of Washington and implemented
through Contract Laboratory Services (CLS, Dr. Wendy Stevens,
Johannesburg, South Africa). Study-site laboratories and clinics
were enrolled in EQA for HIV-1 serology through the National
Health Laboratory Service National Institute of Communicable
Diseases (NHLS/NICD) of South Africa. CD4 testing was assessed
through panels distributed by WHO/QASI/NHLS system [18].
Table 1. HIV-1 and CD4 Diagnostic Assays Used for Study Eligibility.
Assay Type
Standard Test Kits/
Instrument Alternative Test Kits/Instrument
*
HIV-1 paired rapid tests
{ Determine HIV 1/2
(Abbott Labs)
–– – –
Uni-Gold Recombigen
HIV (Trinity Biotech PLC)
Capillus HIV-1/HIV-2
(Trinity Biotech PLC)
–– –
HIV-1 EIA
{ Primary Vironostika Uni-Form II
Ag/Ab(bioMerieux SA)
Vironostika HIV-1 plus O
(bioMerieux SA)
Vironostika HIV
Uni-Form II Ag/Ab
(bioMerieux SA)
Abbott AxSYM HIV
Ag/Ab Combo
(Abbott Labs)
Murex HIV-1.2.0
ELISA (Abbott Labs)
Secondary Enzygnost HIV Integral
(Dade Behring)
Enzygnost (3
rd gen)
(Dade Behring)
Murex HIV Ag-Ab
combination assay
(Murex Biotech)
Biorad HIV type 1
(Viral Lysate and Ecoli
Recombinant Antigen)
Ortho HIV-1/2 Ab
Capture Test
System (Ortho)
CD4 Count Instrument FACSCount Epics XL-MCL Flow
Cytometer
–– –
Method/Reagents TruCount/Becton
Dickenson
PLG CD4/Becton-Coulter – – –
*All assays were required to pass external quality assessment prior to implementation for study-related testing and were required to undergo ongoing external quality
assessment for the duration of the study.
{Paired HIV-1 rapid tests run in parallel.
{Confirmation of rapid test positive results performed with 2 wells on primary EIA kit. If initial EIA results were discrepant, the assay was repeated with one well each
using the primary and secondary EIA kits.
doi:10.1371/journal.pone.0005272.t001
Partners Study Baseline Data
PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5272HIV-1 RNA testing at the University of Washington utilized
proficiency-testing panels from the National Institutes of Health,
Division of AIDS, Virology Quality Assurance Program.
Statistical Analysis
Statistical comparisons were performed using SAS v.9.2 (SAS
Institute, Cary, North Carolina). Differences by region, East versus
Southern Africa, and by HIV-1 infection status were examined
using Chi-square tests for dichotomous factors and linear
regression for continuous measures. Predictors of baseline plasma
HIV-1 RNA in HIV-1 infected participants were examined using
linear regression. Plasma HIV-1 RNA in which the target was not
detected or which were below limit of quantification (BLQ, 240
copies/mL) was set to 120 copies/mL.
Ethics Statement
The Partners Study clinical trial protocol including forms for
written informed consent were reviewed by ethics committees at the
following institutions: South African sites: University of Witwaters-
rand, and University of Cape Town; Botswana site: Republic of
Botswana Ministry of Health, and Harvard School of Public Health;
Zambian sites: Tropical Disease Research Centre, Republic of
Zambia National Ethics Committee, and Emory University;
Rwandan site: Republic of Rwanda National Ethics Committee,
Emory University; Tanzanian site: Kilimanjaro Christian Medical
College, Harvard School of Public Health, and London School of
Hygiene and Tropical Medicine; Ugandan site: Uganda National
Ethics Committee; Kenyan sites: Kenyatta National Hospital, Moi
University, Kenya Medical Research Institute, Indiana University,
University of California San Francisco, and University of Washington.
Results
Figure 1 shows the prescreening, screening and enrollment flow
for this study. The 14 study sites screened 6543 HIV-1 discordant
couples for study eligibility, 3135 of which were identified as HIV-
1 serodiscordant but not enrolled; the major reasons were for
ineligibility were: HIV-1 infected partners with CD4 count ,250
cells/mcL (54%), or HSV-2 seronegative (14%), or pregnant (5%).
Thus, 3408 couples meeting the study eligibility requirements were
enrolled with 66% from East African sites (Table 2). Enrolled
participants were from diverse ethnic origins with 83% self-
identifying into 38 distinct ethnic groups.
Demographic and behavioral characteristics
Table 3 shows demographic and behavioral characteristics of
enrolled couples. Of the 3408 HIV-1 infected participants, 16
enrolled two HIV-1 susceptible partners. HIV-1 infected study
participants were predominantly female (67%) and married (76%)
with a median age of 33 years (IQR 27–39). Conversely, the
majority of HIV-1 susceptible participants were male with a
median age of 35 years (IQR 28–41). Among couples that reported
living together, the median duration of cohabitation was 5 years
(IQR 3–10). Couples reported having a median of 2 children
(IQR 1–4).
At enrollment, couples reported a median of 4 sex acts (IQR 2–
8) (vaginal and/or anal intercourse) in the prior month, and 28%
reported at least one episode of sex without a condom in the past
month. Among all HIV-1 infected and HIV-1 susceptible men,
5% reported sex acts with partners other than their enrolled
partner in the month prior to enrollment, compared to ,2% of
women. Nearly half of women (46% of HIV-1 infected and 44% of
HIV-1 susceptible) reported using only condoms for contracep-
tion, and one-third of women (32% and 33% of HIV-1 infected
and HIV-1 susceptible women, respectively) reported not using
any form of contraception.
Clinical characteristics
A history of GUD (a history of genital ulcers or diagnosis of
GUD in the previous three months) was reported in 6% and 8% of
Figure 1. Prescreening, Screening and Enrollment Flow for HIV-1 serodiscordant couples in the Partners Study.
doi:10.1371/journal.pone.0005272.g001
Partners Study Baseline Data
PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5272HIV-1 infected men and women, respectively; and 2% and 5% of
HIV-1 susceptible men and women, respectively (Table 4). Genital
ulcers were detected on physical exam at enrollment in 3% and 4%
of HIV-1 infected men and women, respectively, compared to 1%
of HIV-1 susceptible partners. Male circumcision, based on genital
exam,wasmore prevalentinHIV-1susceptible comparedtoHIV-1
infected men (55%versus34%,respectively;p,0.001).East African
men were more likely to be circumcised than Southern African men
both among HIV-1 uninfected men (64% versus 37%, p,0.001)
and HIV-1 infected men (39% versus 23%, p,0.001).
Laboratory characteristics
Table 4 shows local and central laboratory data for enrolled
couples. Overall 68% of HIV-1 susceptible participants were
identified as HSV-2 seropositive with higher prevalence in women
compared to men (85% versus 59%, p,0.001; Table 4). Nucleic
acid testing for N. gonorrhoeae and C. trachomatis in both HIV-1
infected and HIV-1 susceptible was positive in #2% of
individuals; T. vaginalis was more prevalent than other STIs and
more commonly detected in women (11% in HIV-1 susceptible
and 16% in HIV-1 infected women) than in men (7% in HIV-1
susceptible and 5% in HIV-1 infected men). Positive RPR tests for
syphilis ranged from 4 to 6%; 3% of all participants had an RPR
titer .1:8 indicative of possible early syphilis.
Median CD4 count at enrollment among HIV-1 infected
women and men was 483 (IQR 355–665) and 424 (IQR 334–571)
cells/mcL, respectively. The median baseline plasma HIV-1 RNA
for HIV-1 infected participants was 4.2 (IQR 3.63–4.76) log10
copies/mL (equivalent to 15,800 copies/mL); with 26% having
HIV-1 RNA ,2000 copies/mL at enrollment and 24% having
.50,000 copies/mL. In univariate analysis, plasma HIV-1 RNA
did not vary by East or Southern African region (p=0.15), but did
vary by age, gender, and CD4 count. In a multivariable regression
model controlling for age and region, CD4 count and gender
remained significantly associated with plasma HIV-1 RNA: men
had plasma HIV-1 RNA 0.24 log10 copies/mL higher than
women; and persons with CD4 counts $500 cells/mcL and 350–
499 cells/mcL had 0.55 log10 and 0.25 log10 copies/mL lower
plasma HIV-1 RNA, respectively, than persons with CD4 counts
250–350 cells/mcL (Table 5).
Discussion
The 3408 HIV-1 serodiscordant couples (6832 individuals)
enrolled in the Partners Study, is the largest, most ethnically and
geographically diverse cohort of HIV-1 serodiscordant couples
ever recruited into an HIV-1 prevention clinical trial.
The HIV-1 serodiscordant couples study design for this clinical
trial was dictated by the need to directly assess whether HSV-2
suppression in an HIV-1 infected partner reduced the risk of HIV-
1 transmission to their sexual partner. In order to identify these
3408 couples, approximately 51,900 couples of unknown HIV-1
serostatus were tested for HIV-1 and 6543 HIV-1 serodiscordant
couples screened for study eligibility. Thus, this trial required
multiple sites and intensive community outreach efforts to promote
couples counseling with strong linkages with HIV-1 voluntary
testing and counseling centers, antenatal clinics, and other clinical
and community organizations.
The demographic, clinical and laboratory characteristics of this
large and diverse cohort of HIV-1 serodiscordant couples suggest
that there are subgroups with distinct HIV-1 transmission risk
profiles. First, the median plasma HIV-1 RNA for HIV-1 infected
partners in this cohort was 4.2 log10 copies/mL, with a quarter of
the cohort having plasma RNA $4.7 log10 copies/mL (50,000
copies/mL). The observational study of monogamous HIV-1
serodiscordant couples from Rakai, Uganda identified plasma
HIV-1 RNA as the strongest predictor of HIV-1 transmission;
persons with HIV-1 RNA $50,000 copies/mL had a 12-fold
increased risk of HIV-1 transmission compared to those with HIV-
1 RNA #3500 copies/mL [19]. Second, nearly one-third of
couples reported at least one episode of unprotected sexual
intercourse in the prior month. Finally, the majority of HIV-1
susceptible participants were HSV-2 seropositive (68%) with
higher prevalence in women as has been reported in other
populations [20]. Previous longitudinal studies have found HSV-2
infection in HIV-1 susceptible people is associated with 1.8 to 3.1-
fold increased risk of HIV-1 acquisition [1,9,21,22].
Notably, a quarter (26%) of HIV-1 infected participants had
HIV-1 RNA ,2000 copies/mL at baseline, which is associated
with a reduced risk of HIV-1 transmission. The cutoff of HIV-1
RNA ,2000 copies/mL has been used to identify viral
‘‘controllers’’, i.e., ART-naı ¨ve individuals with who have main-
tained low HIV-1 RNA and who are at lower risk of HIV-1
transmission to their HIV-1 susceptible sex partners [19].
Prevalence of such viral controllers was less than 12% of HIV-1
infected partners identified through community surveillance in
South Africa [23]. Use of ACD for plasma collection can
underestimate plasma HIV-1 RNA by 0.11 log10 compared to
Table 2. Sites and total enrollment for Partners in Prevention
HSV-2/HIV-1 Transmission Study (Partners Study).
Site Location Couples Enrolled*
Total
East Africa 2250
Kenya
Kisumu 532
Nairobi 416
Eldoret 268
Thika 213
Rwanda
Kigali 153
Tanzania
Moshi 218
Uganda
Kampala 450
Southern Africa 1158
Botswana
Gaborone 325
South Africa
Cape Town 196
Orange Farm 73
Soweto 240
Zambia
Kitwe 91
Lusaka 72
Ndola 161
All regions/sites 3408
*Couples were enrolled at sites for time periods ranging from 5 to 30 months
[14].
doi:10.1371/journal.pone.0005272.t002
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is unlikely that choice of anticoagulant could account for the large
proportion of viral controllers in this cohort. Further study will be
conducted to determine whether low plasma HIV-1 RNA levels at
enrollment is related to undisclosed ART use. The substantial
minority of HIV-1 infected partners with low viral loads in this
cohort may reflect a selection bias arising from recruitment of
couples who had lived together for an average of five years without
transmitting HIV-1. The higher prevalence of viral controllers
among HIV-1 serodiscordant couples may present an opportunity
to examine immunological and genetic factors associated with viral
control in diverse African populations. More than half of the HIV-
1 susceptible males in this cohort were circumcised (54%),
representing a decreased risk of HIV-1 acquisition in those men
who were circumcised, consistent with three recent trials, which
have demonstrated that male circumcision lowers the risk of HIV-
1 acquisition [25,26,27]. Finally, while laboratory-diagnosed
sexually transmitted infections (N. gonorrhoea, C. trachomatis and T.
vaginalis) have previously been identified as risk factors for HIV-1
acquisition and transmission [28], the prevalence of N. gonorrhoeae
and C. trachomatis were very low in this cohort of stable couples
with modestly higher prevalence of T. vaginalis. The role of these
biologic co-factors and relative risk of HIV-1 transmission will be
assessed after follow-up and unblinding is completed.
Recent clinical trials have shown that acyclovir suppressive
therapy among high risk, HSV-2 seropositive/HIV-1 susceptible
persons does not reduce their risk of acquiring HIV-1 [29,30].
Those results may be understood in light of recent data
documenting frequent subclinical HSV-2 reactivation in genital
mucosa [31] with persistent host cellular immune responses,
including HIV-1 susceptible CD4+ and CCR5+ T cells and
plasmacytoid dendritic cells, present in HSV-2 lesions and
persisting for weeks after HSV-2 treatment [32,33,34]. Thus,
while daily antivirals in HSV-2 seropositive/HSV-1 uninfected
persons reduce symptoms of genital ulcers and HSV-2 shedding,
the persistence of HIV-1 susceptible cells associated with the host
immune response to HSV-2 [33,34] likely maintains a high risk of
HIV-1 acquisition.
However, the lack of efficacy observed for HSV-2 suppression
to reduce HIV-1 acquisition may not necessarily pertain to this
trial of HSV-2 suppression to reduce HIV-1 transmission, as the
biologic mechanisms for the two types of interactions differ. The
effect of HSV-2 on HIV-1 transmission reflects the observation
that HSV-2 infection in HIV-1/HSV-2 co-infected persons is
associated with increased plasma [19] and genital HIV-1 RNA
[35]. Although the biologic basis for these in vivo observations is
still not completely understood, in vitro studies indicate that early
and intermediate proteins associated with HSV viral replication
Table 3. Baseline Demographic and Behavioral Characteristics of Enrolled Couples by Gender of HIV-infected Partner.
Characteristic Couples with HIV-infected women Couples with HIV-infected men
HIV-infected
female (#,% )
HIV susceptible
male (#,% )
*
HIV-infected
male (#,% )
HIV susceptible
female
* (#,% )
Total participants 2299 2304 1109 1120
Age (yrs)
Median (IQR) 30 (25–35) 35 (30–42) 37 (32–45) 31 (25–38)
18–24 476 (21%) 117 (5%) 36 (3%) 231 (21%)
25–34 1230 (54%) 982 (43%) 372 (34%)) 502 (45%)
35–44 469 (20%) 752 (33%) 410 (37%) 284 (25%)
44+ 122 (5%) 452 (20%) 288 (26%) 103 (9%)
Partnership characteristics
Married to partner 1683 (73%) – 897 (81%) –
Living with partner 2037 (89%) – 1035 (93%) –
Yrs living w/partner (median, IQR)
{ 5 (2–9) – 6 (3–13) –
Number of children (median, IQR)
{ 2 (1–3) – 3 (2–5) –
Yrs education (median, IQR) 8 (6–10) 9 (7–12) 8 (7–11) 8 (6–10)
Any monthly income 564 (24%) 1377 (60%) 665 (60%) 289 (26%)
Sex acts (in prior month)
Total sex acts (median, IQR)
{ 4 (2–8) – 4 (2–8) –
Unprotected sex acts (median, IQR)
{ 0 (0–1) – 0 (0–1) –
Couples reporting any unprotected sex acts 661 (29%) – 311 (28%) –
Contraception
Condoms 1062 (46%) – – 490 (44%)
Oral 96 (4%) – – 47 (4%)
Injectable 326 (14%) – – 123 (11%)
Other (IUD, sterilization) 188 (8%) – – 135 (12%)
None 727 (32%) – – 372 (33%)
*Sixteen enrolled couples included one HIV-1 infected participant and two HIV-1 uninfected partners.
{Only data collected from the HIV-1 infected partner was for these couples-level characteristics.
doi:10.1371/journal.pone.0005272.t003
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the long terminal repeat region of HIV-1, and genital herpes is
associated with secretion of pro-inflammatory cytokines and
activation of target cells for HIV-1 [36,37,38,39]. Increased
plasma or genital HIV-1 RNA associated with HSV-2 co-infection
would result in exposure of an HIV-1 susceptible person to larger
inoculums of HIV-1 during unprotected sexual intercourse with an
HIV-1/HSV-2 co-infected person. Several proof-of-concept trials
have shown that HSV-2 suppression with daily acyclovir or
valacyclovir in HIV-1/HSV-2 co-infected persons reduces HIV-1
RNA by 0.26–0.53 log10 and cervical or rectal HIV-1 RNA by
0.16–0.35 log10 [6,40,41,42,43]. These reductions in plasma HIV-
1 RNA may indicate that that HSV-2 suppression could also slow
HIV-1 disease progression, as was suggested by a pooled analysis
from the 1990s, which found that high-dose acyclovir, in
combination with nucleoside ART, was associated with a survival
benefit [44]. While these studies are encouraging, the outcome of
the Partners Study is of critical importance to directly test the
hypothesis that HSV-2 suppression will reduce HIV-1 transmis-
sion or HIV-1 disease progression.
Overall, the demographic and behavioral characteristics of this
study cohort are similar to other cohorts of HIV-1 serodiscordant
couples recruited for research studies in Africa [8,45]. Notably
however, the proportion of HIV-1 infected participants that were
women (67%) is higher than the 30–50% previously reported
[8,45,46,47,48]. The higher proportion of female HIV-1 infected
partners among Partners couples enrolled in the Partners trial may
derive from the preponderance of VCT and antenatal clinics for
recruitment. Given lower HIV-1 testing rates among men and a
tendency for African men to rely on their partners to be tested
(assuming their partner’s HIV serostatus is their own) [49], other
recruitment strategies, such as home-based VCT [50], may be
needed for future HIV-1 prevention trials to identify a higher
proportion of HIV-1 serodiscordant couples with HIV-1 infected
men.
HIV-1 serodiscordant couples are increasingly becoming a focus
of HIV-1 prevention research particularly in Africa
[51,52,53,54,55], in part due to the fact that HIV-1 discordance
is common in many locations in Africa and that a substantial
fraction of HIV-1 infections are transmitted in stable couples
[14,47]. Estimates of HIV-1 seroincidence in HIV-1 serodiscor-
dant couples in sub-Saharan Africa vary greatly [55], but have
been reported as high as 12% [19] to 22% [56] per year. HIV-1
discordant couples are clearly at high risk of HIV-1 transmission,
Table 4. Baseline Clinical and Laboratory Characteristics of Enrolled Couples by Gender of HIV-1 Infected Partner.
Characteristic Couples with HIV-infected women Couples with HIV-infected men
HIV-infected
female (#,% )
HIV susceptible
male (#,% )
*
HIV-infected
male (#,% )
HIV susceptible
female
* (#,% )
Symptoms of GUD (previous 3 months) 174 (8%) 46 (2%) 63 (6%) 54 (5%)
Syndromic STI diagnosis (previous 3 months)
Vaginitis 251 (11%) – – 51 (5%)
Cervicitis 28 (1%) – – 9 (1%)
PID 50 (2%) – – 19 (2%)
Urethritis 65 (3%) 50 (2%) 25 (2%) 17 (2%)
Physical exam findings
Cervical tenderness 59 (3%) – – 20 (2%)
Cervical mucopus 56 (2%) – – 27(2%)
Circumcision (males only) – 1255 (55%) 381 (34%) –
Genital Ulcers 92 (4%) 31 (1%) 34 (3%) 14 (1%)
CD4 count (cells/mcL) (median, IQR) 483 (355–665) – 424 (334–571) –
HIV-1 Plasma RNA
Log10 Median (IQR) 4.1 (3.5–4.6) – 4.4 (3.8–4.9) –
BLQ** 288 (14%) – 67 (6%) –
,2000 copies/mL 335 (15%) – 108 (10%) –
2000–10,000 copies/mL 572 (25%) – 221 (20%) –
.10,000 copies/mL 1078 (47%) – 702 (63%) –
HSV-2 Western Blot
HSV-2 seropositive * 1362 (59%) * 954 (85%)
Sexually Transmitted Infections
N. gonorrhoeae positive (TMA) 40 (2%) 11 (1%) 9 (1%) 12 (1%)
C. trachomatis positive (TMA) 54 (2%) 64 (3.0%) 14 (1%) 19 (2%)
T. vaginalis positive (TMA) 367 (16%) 157 (7%) 52 (5%) 123 (11%)
Positive RPR 140 (6%) 107 (5%) 61 (6%) 43 (4%)
RPR titer (.1:8) 94 (4%) 62 (3%) 41 (4%) 23 (2%)
*All HIV-1 infected participants were HSV-2 seropositive at enrollment based on Focus EIA (index value .3.4) testing at the study site.
**Below Limit of Quantitation.
doi:10.1371/journal.pone.0005272.t004
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interventions. Efforts to recruit HIV-1 discordant couples for
research efforts helps build public health infrastructure for
identifying such couples. The Partners Study has now clearly
demonstrated that large numbers of HIV-1 discordant couples at
high risk for HIV-1 transmission can be successfully recruited to
an HIV-1 prevention clinical trial.
Acknowledgments
The members of the Partners in Prevention HSV/HIV Transmission
Study Team are: University of Washington Coordinating Center, Seattle, USA:
Connie Celum (Principal Investigator), Anna Wald (Protocol Co-chair),
Jairam Lingappa (Medical Director), Amalia Magaret (Protocol Statisti-
cian), James Hughes (Protocol Statistician), Lawrence Corey, Jared Baeten,
M. Juliana McElrath, Robert Coombs, Rhoda Morrow, William
Whittington, James Mullins (Co-investigators)
Study Sites, Site Principal Investigators and Study Coordinators: Cape Town,
South Africa (University of Cape Town): David Coetzee, Mercy
Kamupira; Eldoret, Kenya (Moi University, Indiana University):
Kenneth Fife, Edwin Were, Cosmas Apaka; Gaborone, Botswana
(Botswana Harvard Partnership): Max Essex, Joseph Makhema, Patrick
Ndase; Kampala, Uganda (Infectious Disease Institute, Makerere
University): Elly Katabira, Allan Ronald, Linda Kavuma; Kigali, Rwanda
(Rwanda Zambia HIV Research Group, and Emory University): Susan
Allen, Kayetesi Kayatenkore, Etienne Karita, Brigitte Bekan; Kisumu,
Kenya (Kenya Medical Research Institute, University of California San
Francisco): Elizabeth Bukusi, Craig Cohen, Josephine Odoyo; Kitwe,
Zambia (Rwanda Zambia HIV Research Group, and Emory University):
Susan Allen, William Kanweka, Rachel Blacher; Lusaka,Z a m b i a
(Rwanda Zambia HIV Research Group, and Emory University): Susan
Allen, Bellington Vwalika; Moshi, Tanzania (Kilimanjaro Christian
Medical College, Harvard University): Saidi Kapiga, Rachel Manongi,
Paul Magao; Nairobi, Kenya (University of Nairobi, University of
Washington): Carey Farquhar, Grace John-Stewart, James Kiarie,
Harrison Tamooh; Ndola, Zambia (Rwanda Zambia HIV Research
Group, and Emory University): Susan Allen, Mubiana Inambao, Frank
Wong; Orange Farm, South Africa (Reproductive Health & HIV
Research Unit, University of the Witwatersrand): Sinead Delaney-
Moretlwe, Helen Rees, Nonkululeko Mlaba; Soweto, South Africa
(Perinatal HIV Research Unit, University of the Witwatersrand): Guy de
Bruyn, Glenda Gray, James McIntyre, Puleng Dhlamini; Thika, Kenya
(University of Nairobi, University of Washington): Nelly Rwamba Mugo,
Kenneth Ngure.
Batch nucleic acid testing for sexually transmitted infections was
performed at the Research Laboratory on Sexually Transmitted Infections
at the University of Washington (William Whittington and Ana Maria Xet-
Mull).
Confirmatory HIV-1 plasma HIV-1 RNA quantification was performed
at the University of Washington Retrovirology Lab (Robert Coombs and
Joan Dragavon)
Confirmatory HSV-2 serology testing was performed at the University of
Washington Virology Lab (Rhoda Morrow and Anne Cent)
DF/Net Research, Inc. (Seattle, USA) was contracted to provide data
management. CLS (University of the Witwatersrand, Johannesburg, South
Africa) was contracted to provide study site laboratory oversight.
GenProbe, provided reagents for the Aptima Combo 2 assay for
gonorrhea and chlamydial infection and the TV-TMA assay for T.
vaginalis.
We gratefully acknowledge the invaluable contributions of the study
participants.
Author Contributions
Conceived and designed the experiments: JRL LC AW CC. Performed the
experiments: JRL NM AM EB CRC EK AR JNK CF GJS JM ME EW
KHF GdB GG JM RM SK DC SA MI KK EK WK SDM HR BV RWC
RM WW LC AW CC. Analyzed the data: JRL EK ASM JB WW AW CC.
Contributed reagents/materials/analysis tools: JRL NM AM ASM JB EB
CRC EK AR JNK CF GJS JM ME EW KHF GdB GG JM RM SK DC
SA MI KK EK WK SDM HR BV RWC RM WW LC AW CC. Wrote
the paper: JRL NM AM ASM JB EB CRC EK AR JNK CF GJS JM ME
EW KHF GdB GG JM RM SK DC SA MI KK EK WK SDM HR BV
RWC RM WW LC AW CC.
Table 5. Determinants of Baseline Plasma RNA in Partners Study HIV-1 Discordant Couples.
Factor
HIV-1 RNA
(mean, log10)
Univariate
Analysis (P-value) Multivariable Analysis
Change in HIV-1 RNA
vs Referent (95% CI) P-value
Age
18–24 4.04 (3.96, 4.12) Referent — Referent
25–34 4.01 (3.96, 4.06) 0.52 20.11 (20.2, 0.02) 0.01
35–44 4.14 (4.08, 4.20) 0.05 20.07 (20.17, 0.03) 0.17
44+ 4.29 (4.21, 4.38) ,0.0001 20.02 (20.14, 0.1)* 0.76
Gender
Women 3.98 (3.94, 4.02) Referent — Referent
Men 4.29 (4.24, 4.34) ,0.0001 0.24 (0.3, 0.18) ,0.0001
CD4 count
250–349 cells/mm
3 4.41 (4.35, 4.47) Referent — Referent
350–499 cells/mm
3 4.16 (4.11, 4.21) ,0.0001 20.25 (20.33, 20.17) ,0.0001
500+ cells/mm
3 3.83 (3.79, 3.88) ,0.0001 20.55 (20.63, 20.48) ,0.0001
Region
Southern Africa 4.05 (4.00, 4.10) Referent — Referent
East Africa 4.10 (4.06, 4.14) 0.16 0.07 (0.01, 0.14) 0.02
*The impact of older age on HIV-1 RNA is likely accounted for by interaction between age and gender in the multivariable analysis.
doi:10.1371/journal.pone.0005272.t005
Partners Study Baseline Data
PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5272References
1. Corey L, Wald A, Celum CL, Quinn TC (2004) The effects of herpes simplex
virus-2 on HIV-1 acquisition and transmission: a review of two overlapping
epidemics. J Acquir Immune Defic Syndr 35: 435–445.
2. Mole L, Ripich S, Margolis D, Holodniy M (1997) The impact of active herpes
simplex virus infection on human immunodeficiency virus load. J Infect Dis 176:
766–770.
3. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L (2002) Changes in plasma
human immunodeficiency virus type 1 RNA associated with herpes simplex
virus reactivation and suppression. J Infect Dis 186: 1718–1725.
4. Baeten JM, McClelland RS, Corey L, Overbaugh J, Lavreys L, et al. (2004)
Vitamin A supplementation and genital shedding of herpes simplex virus among
HIV-1-infected women: a randomized clinical trial. J Infect Dis 189: 1466–1471.
5. Mbopi-Keou FX, Legoff J, Gresenguet G, Si-Mohamed A, Matta M, et al.
(2003) Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and
proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women.
J Acquir Immune Defic Syndr 33: 121–124.
6. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al.
(2007) Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal
and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a
randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196:
1500–1508.
7. Zuckerman RA, Celum C, e al (2009) Seminal HIV viral load in HIV-1/HSV-2
co-infected men. AIDS, In press.
8. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al.
(2001) Probability of HIV-1 transmission per coital act in monogamous,
heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357:
1149–1153.
9. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr, et al. (2008)
Genital herpes has played a more important role than any other sexually
transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3: e2230.
10. Freeman EE, Orroth KK, White RG, Glynn JR, Bakker R, et al. (2007)
Proportion of new HIV infections attributable to herpes simplex 2 increases over
time: simulations of the changing role of sexually transmitted infections in sub-
Saharan African HIV epidemics. Sex Transm Infect 83 Suppl 1: i17–24.
11. Wald A (2004) Synergistic interactions between herpes simplex virus type-2 and
human immunodeficiency virus epidemics. Herpes 11: 70–76.
12. Lingappa JR, Celum C (2007) Clinical and therapeutic issues for herpes simplex
virus-2 and HIV co-infection. Drugs 67: 155–174.
13. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, et al. (2001) Virologic and
immunologic determinants of heterosexual transmission of human immunode-
ficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 17: 901–910.
14. Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, et al. (2008)
Regional Differences in Prevalence of HIV-1 Discordance in Africa and
Enrollment of HIV-1 Discordant Couples into an HIV-1 Prevention Trial. PLoS
ONE 3: e1411.
15. Centers for Disease Control and Prevention (November 2007) Couples HIV
Counseling and Testing.
16. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J (2004)
Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and
HSV-2 antibodies among women in ten diverse geographical locations. Clin
Microbiol Infect 10: 530–536.
17. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, et al. (2007) Rapid
antigen testing compares favorably with transcription-mediated amplification
assay for the detection of Trichomonas vaginalis in young women. Clin Infect
Dis 45: 194–198.
18. Glencross DK, Aggett HM, Stevens WS, Mandy F (2008) African regional
external quality assessment for CD4 T-cell enumeration: development,
outcomes, and performance of laboratories. Cytometry B Clin Cytom 74 Suppl
1: S69–79.
19. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral
load and heterosexual transmission of human immunodeficiency virus type 1.
Rakai Project Study Group. N Engl J Med 342: 921–929.
20. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, et al. (1997)
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med
337: 1105–1111.
21. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006)
Herpes simplex virus 2 infection increases HIV acquisition in men and women:
systematic review and meta-analysis of longitudinal studies. AIDS 20: 73–83.
22. Wald A, Link K (2002) Risk of human immunodeficiency virus infection in
herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis
185: 45–52.
23. Auvert B, Males S, Puren A, Taljaard D, Carael M, et al. (2004) Can highly
active antiretroviral therapy reduce the spread of HIV?: A study in a township of
South Africa. J Acquir Immune Defic Syndr 36: 613–621.
24. Lew J, Reichelderfer P, Fowler M, Bremer J, Carrol R, et al. (1998)
Determinations of levels of human immunodeficiency virus type 1 RNA in
plasma: reassessment of parameters affecting assay outcome. TUBE Meeting
Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and
Standardization in Pediatrics. J Clin Microbiol 36: 1471–1479.
25. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005)
Randomized, controlled intervention trial of male circumcision for reduction of
HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298.
26. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male
circumcision for HIV prevention in young men in Kisumu, Kenya: a
randomised controlled trial. Lancet 369: 643–656.
27. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male
circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Lancet 369: 657–666.
28. Rottingen JA, Cameron DW, Garnett GP (2001) A systematic review of the
epidemiologic interactions between classic sexually transmitted diseases and
HIV: how much really is known? Sex Transm Dis 28: 579–597.
29. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir
on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men
who have sex with men: a randomised, double-blind, placebo-controlled trial.
Lancet 371: 2109–2119.
30. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. (2008)
Effect of Herpes Simplex Suppression on Incidence of HIV among Women in
Tanzania. N Engl J Med 358: 1560–1571.
31. Mark KE, Wald A, Magaret AS, Selke S, Olin L, et al. (2008) Rapidly cleared
episodes of herpes simplex virus reactivation in immunocompetent adults.
J Infect Dis 198: 1141–1149.
32. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, et al. (2007)
Negative mucosal synergy between Herpes simplex type 2 and HIV in the
female genital tract. Aids 21: 589–598.
33. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, et al. (2007) Virus-specific
CD8+ T cells accumulate near sensory nerve endings in genital skin during
subclinical HSV-2 reactivation. J Exp Med 204: 595–603.
34. Zhu J, Woodward A, Klock A, Peng T, Johnston C, et al. (2009) Genital HSV-2
Infection Imprints a Marked Enrichment and Long Term Persistence of HIV
Receptor Positive Cells in the Genital Tract., Keystone Symposia on Prevention
of HIV/AIDS, Abstract #X3-123, Keystone, Colorado, March 2009.
35. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, et al. (1998)
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-
infected men. JAMA 280: 61–66.
36. Albrecht MA, DeLuca NA, Byrn RA, Schaffer PA, Hammer SM (1989) The
herpes simplex virus immediate-early protein, ICP4, is required to potentiate
replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol 63:
1861–1868.
37. Golden MP, Kim S, Hammer SM, Ladd EA, Schaffer PA, et al. (1992)
Activation of human immunodeficiency virus by herpes simplex virus. J Infect
Dis 166: 494–499.
38. Palu G, Benetti L, Calistri A (2001) Molecular Basis of the Interactions between
Herpes Simplex Viruses and HIV-1. Herpes 8: 50–55.
39. Tremblay M, Gornitsky M, Wainberg MA (1989) Active replication of human
immunodeficiency virus type 1 by peripheral blood mononuclear cells following
coincubation with herpes viruses. J Med Virol 29: 109–114.
40. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, et al. (2008)
Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and
Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized,
Placebo-Controlled, Cross-Over Trial. J Infect Dis 198: 1804–1808.
41. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, et al.
(2008) Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in
HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune
Defic Syndr 49: 77–83.
42. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, et al. (2007)
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
N Engl J Med 356: 790–799.
43. Delany SC, Mlaba N, Akpomiemie G, Capovilla A, Stevens W, et al. (2008)
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-
infected women: a randomised placebo-controlled trial in South Africa. AIDS,
In Press.
44. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, et al. (1998) Clinical
efficacy of high-dose acyclovir in patients with human immunodeficiency virus
infection: a meta-analysis of randomized individual patient data. J Infect Dis
178: 349–359.
45. Kempf MC, Allen S, Zulu I, Kancheya N, Stephenson R, et al. (2008)
Enrollment and retention of HIV discordant couples in Lusaka, Zambia.
J Acquir Immune Defic Syndr 47: 116–125.
46. de Walque D (2006) Discordant Couples - HIV infection among couples in
Burkina Faso, Cameroon, Ghana, Kenya, and Tanzania The World Bank. 28 p.
47. Freeman EE, Glynn JR, Study Group on Heterogeneity of HIV Epidemics in
African Cities (2004) Factors affecting HIV concordancy in married couples in
four African cities. AIDS 18: 1715–1721.
48. Stephenson R, Barker J, Cramer R, Hall MA, Karita E, et al. (2008) The
demographic profile of sero-discordant couples enrolled in clinical research in
Rwanda and Zambia. AIDS Care 20: 395–405.
49. Morrill AC, Noland C (2006) Interpersonal issues surrounding HIV counseling
and testing, and the phenomenon of "testing by proxy". J Health Commun 11:
183–198.
50. Tumwesigye E, Asiimwe S, Muganzi S, Achom M, Kabatesi D, et al. (2008)
High HIV Prevalence among Males in Discordant Partnerships in a Full Access
Door–Door VCT Program in Rural Uganda. 15th Congress on Retroviruses
and Opportunistic Infections (CROI). Boston, Massachusetts.
Partners Study Baseline Data
PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e527251. Allen S, Karita E, Chomba E, Roth DL, Telfair J, et al. (2007) Promotion of
couples’ voluntary counselling and testing for HIV through influential networks
in two African capital cities. BMC Public Health 7: 349.
52. Allen S, Lindan C, Serufilira A, Van de Perre P, Rundle AC, et al. (1991)
Human immunodeficiency virus infection in urban Rwanda. Demographic and
behavioral correlates in a representative sample of childbearing women. Jama
266: 1657–1663.
53. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, et al. (2003) Sexual
behavior of HIV discordant couples after HIV counseling and testing. Aids 17:
733–740.
54. Bunnell RE, Nassozi J, Marum E, Mubangizi J, Malamba S, et al. (2005) Living
with discordance: knowledge, challenges, and prevention strategies of HIV-
discordant couples in Uganda. AIDS Care 17: 999–1012.
55. Guthrie BL, de Bruyn G, Farquhar C (2007) HIV-1-discordant couples in sub-
Saharan Africa: explanations and implications for high rates of discordancy.
Curr HIV Res 5: 416–429.
56. Allen S, Tice J, Van de Perre P, Serufilira A, Hudes E, et al. (1992) Effect of
serotesting with counselling on condom use and seroconversion among HIV
discordant couples in Africa. Bmj 304: 1605–1609.
Partners Study Baseline Data
PLoS ONE | www.plosone.org 10 April 2009 | Volume 4 | Issue 4 | e5272